Trigeminal Neuralgia
📧 Sign up to get email alerts when something new happens for Trigeminal Neuralgia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-01-29FDA Approved: CARBAMAZEPINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for carbamazepine submitted by ANI Pharmaceuticals, Inc.
-
FDA approval · 2024-01-29FDA Approved: CARBAMAZEPINE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application to permit Chartwell RX, LLC to market a generic carbamazepine product under an ANDA.
-
FDA approval · 2024-01-29FDA Approved: CARBAMAZEPINE — Supplemental Application (Zydus Pharmaceuticals (USA) Inc.)
FDA approved a supplemental application for carbamazepine from Zydus Pharmaceuticals (USA) Inc., updating the approved generic product.
-
FDA approval · 2024-01-29FDA Approved: CARBAMAZEPINE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for carbamazepine by Rising Pharma Holdings, Inc.
-
FDA approval · 2024-01-09FDA Approved: CARBAMAZEPINE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for carbamazepine by Upsher-Smith Laboratories, with changes to its approved labeling and indication…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-12-22FDA Approved: CARBAMAZEPINE — Supplemental Application (NIVAGEN PHARMACEUTICALS, INC.)
FDA approved a supplemental application for Carbamazepine from NIVAGEN Pharmaceuticals, authorizing changes to the generic product under the…
-
FDA approval · 2023-12-11FDA Approved: CARBAMAZEPINE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for carbamazepine filed by Unichem Pharmaceuticals (USA), Inc., signaling an approved change to …
-
FDA approval · 2023-09-13FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Tegretol (carbamazepine) filed by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia [Phase 2]
Phase 2 clinical trial of incobotulinum toxin for trigeminal neuralgia has been terminated with results posted.
-
CLINICAL_TRIALS withdrawal · 2023-05-06Clinical Trial Update: 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia [Phase 3]
A Phase 3 clinical trial of BIIB074 (802NP302) for trigeminal neuralgia was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-05-06Clinical Trial Update: 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia [Phase 3]
Phase 3 trial of BIIB074 for trigeminal neuralgia was withdrawn.
-
FDA approval · 2023-03-24FDA Approved: CARBAMAZEPINE — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA's original ANDA for carbamazepine (generic anticonvulsant). This marks the availability of a generic carbamaz…
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: 5% Lidocaine-medicated Plaster for the Treatment of Trigeminal Neuralgia [Phase 4]
Phase 4 clinical trial update on a 5% lidocaine medicated plaster for treating trigeminal neuralgia has completed.
-
FDA approval · 2023-03-02FDA Approved: CARBAMAZEPINE ER — Original Application (Epic Pharma, LLC)
FDA approves the first original-application generic Carbamazepine ER from Epic Pharma, LLC under ANDA 216235. This extended-release formulat…
-
FDA approval · 2022-12-02FDA Approved: CARBAMAZEPINE — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved the original application for a generic carbamazepine product from Ingenus Pharmaceuticals, LLC.
-
FDA approval · 2022-11-21FDA Approved: EPITOL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for EPITOL (carbamazepine) from Teva Pharmaceuticals USA, Inc. This action approves changes to the p…
-
FDA approval · 2022-11-09FDA Approved: CARBAMAZEPINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for carbamazepine filed by ANI Pharmaceuticals, Inc.
-
FDA approval · 2022-11-08FDA Approved: CARBAMAZEPINE — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for Carbamazepine submitted by Apotex Corp., a generic formulation.
-
FDA approval · 2022-11-08FDA Approved: CARBAMAZEPINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for carbamazepine from Apotex Corp., approving changes to the approved generic product.
-
FDA approval · 2022-10-06FDA Approved: CARBAMAZEPINE — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' generic carbamazepine under Original Application ANDA214277.
-
FDA approval · 2022-08-22FDA Approved: CARBAMAZEPINE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved the Original Application for generic carbamazepine from Unichem Pharmaceuticals (USA), Inc.
-
FDA approval · 2022-08-18FDA Approved: CARBAMAZEPINE — Original Application (Northstar Rx LLC)
FDA approved the original generic application for Carbamazepine from Northstar Rx LLC, authorizing a generic version of the anticonvulsant. …
-
FDA approval · 2022-03-31FDA Approved: CARBAMAZEPINE ER — Original Application (Bostal LLC)
FDA approved Bostal LLC's original-application generic extended-release carbamazepine (CARBAMAZEPINE ER), marking the first approval of this…
-
FDA approval · 2021-12-01FDA Approved: CARBATROL — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for CARBATROL (carbamazepine) from Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2021-10-15Clinical Trial Update: Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial [Phase 4]
A Phase 4 clinical trial compares the efficacy of carbamazepine and oxcarbazepine for treating trigeminal neuralgia. Current status is unkno…